Ipamorelin and CJC-1295: The Growth Hormone Stack Explained

If you spend any time in peptide research communities, you'll see ipamorelin and CJC-1295 treated as a single unit — almost always listed together, almost always used together. Understanding why requires a quick look at how growth hormone release actually works.

Growth Hormone and Its Release

Your pituitary gland releases growth hormone in pulses throughout the day, with the largest pulse typically occurring shortly after you fall asleep. The timing and size of these pulses are governed by two main hormones: growth hormone releasing hormone (GHRH), which promotes release, and somatostatin, which suppresses it. The balance between these two determines your GH output.

Aging disrupts this system. The pituitary's GH output declines significantly with age — some studies suggest output in your 40s is roughly half what it was in your 20s. The gland itself remains capable; it's the signalling that changes. This is the window that growth hormone secretagogues are designed to work in.

What Ipamorelin Does

Ipamorelin is a growth hormone releasing peptide (GHRP). It works by binding to the ghrelin receptor (also called the GH secretagogue receptor) in the pituitary and hypothalamus, stimulating GH release. It's a selective compound — among the GHRPs, it's known for having minimal effect on cortisol and prolactin, which are common side effects of other peptides in this class like GHRP-6 and GHRP-2.

The GH pulse that ipamorelin produces mimics a natural release rather than the sustained elevation you'd get from exogenous GH injections. This is considered an advantage for people who want to amplify their natural GH output rather than replace it — the pituitary remains responsive, and the feedback loops that regulate GH secretion stay intact.

What CJC-1295 Does

CJC-1295 is a modified form of growth hormone releasing hormone. Where ipamorelin works at the ghrelin receptor, CJC-1295 works at the GHRH receptor — a different pathway, producing a complementary effect. It extends and amplifies the signal that tells the pituitary to release GH.

There are two versions of CJC-1295 that cause considerable confusion: CJC-1295 with DAC and CJC-1295 without DAC (the latter also known as Modified GRF 1-29, or Mod GRF). The DAC (Drug Affinity Complex) version has a much longer half-life — around a week — which produces sustained GH elevation rather than pulsatile release. Most people interested in mimicking natural GH patterns use the version without DAC, which has a half-life closer to 30 minutes and produces a more physiological pulse.

Why They're Stacked

Ipamorelin and CJC-1295 (without DAC) work on different receptors and produce GH release through different mechanisms. Used together, they create a synergistic effect — the combined pulse is larger than either compound produces alone. It's analogous to pressing the accelerator (GHRH signal) while simultaneously releasing the brake (ghrelin receptor stimulation), which results in a GH pulse that more closely approximates what a younger pituitary might produce naturally.

Timing matters. Both compounds are typically injected 30–60 minutes before bed to take advantage of the body's natural overnight GH pulse window, amplifying what's already happening rather than creating an entirely artificial pattern.

What People Use It For

The primary reported uses are body composition — favouring fat loss and lean mass retention — sleep quality, recovery speed, and skin and connective tissue health. These align with what elevated GH levels would be expected to do: improving lipolysis, accelerating protein synthesis, and supporting collagen production.

It's worth being specific about what this isn't: it's not the same as injecting exogenous growth hormone. The peak GH levels achieved through secretagogue use are significantly lower than those from direct GH injections, and the cost-to-effect ratio is correspondingly different. Secretagogues are essentially a way to optimise your natural GH output; they're not a replacement for the pharmaceutical product.

The Research Situation

CJC-1295 has some actual human trial data — a 2006 study published in the Journal of Clinical Endocrinology and Metabolism showed dose-dependent increases in GH and IGF-1 levels in healthy adults, which was encouraging. Ipamorelin's clinical data is thinner but positive in the animal literature.

Neither compound has completed the clinical trial process for any therapeutic indication, which means their use remains in research territory. The GH-axis is also not without complexity — sustained IGF-1 elevation is something that warrants monitoring, given the theoretical links between IGF-1 signalling and cell proliferation. This is a reason why bloodwork is considered basic practice among people using these compounds seriously, not an optional extra.

Practical Considerations

Both compounds require reconstitution and subcutaneous injection. Common protocols use 100–300mcg of each, injected together, three to five nights per week. Fasting for at least two hours before injection is typically recommended, because insulin and somatostatin levels rise after eating and blunt the GH response.

Cycles are often run for 12–16 weeks followed by a break, though some people use these compounds continuously at lower doses. The logic of cycling is to maintain pituitary sensitivity — there's some evidence that continuous stimulation can lead to receptor desensitisation over time.